Eculizumab for severe kidney and blood clotting emergencies in adults
Part of Blood & lymphatic, Heart & circulation, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial studies eculizumab, a targeted blood-clotting and immune system medicine, for adults hospitalized with hypertensive emergency–associated hemolytic uremic syndrome (a serious condition affecting kidneys and blood). It aims to see whether the drug can improve outcomes after this life-threatening event.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You were hospitalized for hypertensive emergency–associated hemolytic uremic syndrome within the last 10 days.
- You have severe high blood pressure plus signs of blood cell damage (anemia/low platelets/abnormal tests or blood smear changes) and usually kidney injury or organ symptoms.
- You can use effective birth control during the study and for at least 5 months after the last dose, if you can become pregnant.
- You are able to sign written informed consent and understand the study as required by the team.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the drug ravulizumab for people with aHUS (a rare blood and kidney condition). It aims to see if the drug can help improve blood counts and kidney function.
This trial tests a new medicine for people with a rare blood disorder called atypical hemolytic uremic syndrome (aHUS) that is still active despite other treatments. The drug aims to stop the ongoing damage to blood cells and kidneys.
This trial tests three experimental antibodies given to people with end-stage kidney disease who are on hemodialysis. It aims to see if these drugs are safe and how they affect blood clotting in this group.
This trial tests a drug called eculizumab (also known as Soliris) in people who are in the ICU with severe Covid-19 and a lung condition called ARDS. The drug may help calm an overactive immune response that causes lung damage.
This study tests a new medicine called INM004 in children with STEC-HUS, a serious illness that damages the kidneys and blood cells. It may help speed up recovery and prevent complications.
This trial tests whether eculizumab can safely help people with a serious blood vessel complication called TA-TMA after a stem cell transplant. You may be eligible if you have high-risk features and haven't improved with initial care.
Hear when a new Hypertensive Emergency-associated Hemolytic Uremic Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.